Warren Buffett Thinks Investors Are "Gambling" Right Now. Here are 2 Stocks That Should Be Safe Bets.

The article highlights defensive healthcare exposure via Merck and Johnson & Johnson, emphasizing long dividend streaks (MRK increased for 26 consecutive years to a 5% higher quarterly dividend of $0.85; JNJ increased for 64 consecutive years with a 3% raise). It cites strong recent operating momentum—Merck Q2 sales of $16.6B (+5% YoY, with Keytruda $8.4B, +5%) and Johnson & Johnson Q2 revenue of $25.3B (+6.6% YoY, with Darzalex Faspro $4.2B, +18.9%). Multiple positive pipeline/regulatory catalysts are noted (e.g., FDA approvals/clears including J&J’s Darzalex Faspro indication and AI-enabled Monarch Quest 3), alongside a market backdrop cautioning against speculation.

Analysis

The market implication is less about dividend yield and more about factor rotation: JNJ and MRK are natural homes for capital if investors keep paying up for cash-flow durability while questioning crowded growth. In the next 1-3 months, that can create passive-support and lower-volatility outperformance even if absolute upside is modest. The first-order beneficiaries are the stocks themselves; the second-order losers are capital-light growth names that depend on a stable discount rate and uninterrupted risk appetite.

MRK's real issue is not today’s earnings, it’s terminal value around the oncology franchise. Anything that extends the life of its immuno-oncology cash engine matters more than the initial dollar size of the new data, because it pushes the patent-cliff debate further out and reduces the market's need to haircut the multiple. The melanoma-vaccine angle is most valuable as platform validation; MRNA gets optionality, but MRK is the cleaner economic beneficiary if the program becomes registrational. Falsifier: any sign that Keytruda growth slows faster than the pipeline can replace it.

For JNJ, the near-term catalyst is sentiment, not immediate revenue. Robotic-surgery approvals and other medtech wins are long-cycle adoption stories, so the P&L contribution should ramp over quarters, not weeks; the risk is that hospitals delay capex if the macro softens. Contrarian view: the consensus is treating these as "safe and cheap," but they are really "safer and expensive enough" — better than speculative growth, yet not immune to multiple compression if rates fall and leadership rotates back to high-beta tech.

Key Decisions for Investors

• Add JNJ on 2-3% pullbacks over the next 1-2 weeks; hold 6-12 months. Use it as a low-volatility quality compounder, not a momentum trade.
• Add MRK, but size below JNJ because the long-duration oncology story still carries patent-cliff risk. Hold 6-12 months; thesis breaks if management signals pipeline replacement is insufficient.
• Fund healthcare quality exposure by trimming a slice of crowded high-multiple growth names; if expressing the bubble concern directly, do it as a portfolio rotation, not a standalone short.
• Do not chase MRNA on the partnership headline alone; keep it on watch for confirmatory oncology data and clearer regulatory path before taking risk.